This is a working overview of HPLC-UV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-06. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
== Prognosis == The prognosis depends on the underlying cause and whether any complications occur. Rhabdomyolysis complicated by acute kidney impairment in patients with traumatic injury may have a mortality rate of 20%. Admission to the intensive care unit is associated with a mortality of 22% in the absence of acute kidney injury, and 59% if kidney impairment occurs. Most people who have sustained kidney impairment due to rhabdomyolysis fully recover their kidney function.
During the period of the British War Cabinet discussions leading up to the declaration, the war had reached a period of stalemate. On the Western Front the tide would first turn in favour of the Central Powers in spring 1918, before decisively turning in favour of the Allies from July 1918 onwards. Although the United States declared war on Germany in the spring of 1917, it did not suffer its first casualties until 2 November 1917, at which point President Woodrow Wilson still hoped to avoid dispatching large contingents of troops into the war. The Russian forces were known to be distracted by the ongoing Russian Revolution and the growing support for the Bolshevik faction, but Alexander Kerensky's Provisional Government had remained in the war; Russia only withdrew after the final stage of the revolution on 7 November 1917.
Glutathione S-transferase A3 is an enzyme that in humans is encoded by the GSTA3 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. These enzymes are involved in cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic compounds. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase belonging to the alpha class genes that are located in a cluster mapped to chromosome 6. Genes of the alpha class are highly related and encode enzymes with glutathione peroxidase activity. However, during evolution, this alpha class gene diverged accumulating mutations in the active site that resulted in differences in substrate specificity and catalytic activity. The enzyme encoded by this gene catalyzes the double bond isomerization of precursors for progesterone and testosterone during the biosynthesis of steroid hormones. An additional transcript variant has been identified, but its full length sequence has not been determined.
Sources: en.wikipedia.org
Seek political support for policies. Legitimize policies. This has been clearer in Ecuador, Bolivia and Peru. New governments in Ecuador and Peru have approached policy institutes for support for already defined policies. In Bolivia, the government of Evo Morales has been working with Non-Government Organizations (NGOs) and other research institutes to do the same. However, in Chile, many think tanks during the 1990s seemed to endorse and maintain the legitimacy of policies implemented during the previous decade by the military dictatorship headed by Pinochet. Act as Spaces for debate. In this case think tanks serve as sounding boards for new policies. In Chile, during the Pinochet dictatorship, many left wing intellectuals and researchers found 'asylum' in think tanks. In Ecuador, think tanks are seen as spaces where politicians can test the soundness of their policies and government plans. Provide financial channels for political parties or other interest groups. In Ecuador and Bolivia, German foundations have been able to provide funds to think tanks that work with certain political parties. This method has provided support to the system as a whole rather than individual CSOs. Supply expert staff of policy-makers. In Peru after the end of the Fujimori regime, and in Chile after the fall of Pinochet, think tank staff left to form part of the new governments. In the United States, the role of major think tanks is precisely that: host scholars for a few months or years and then lose them to government employ.
==== Water industry ==== The water industry provides drinking water and wastewater services (including sewage treatment) to households and industry. Water supply facilities include water wells, cisterns for rainwater harvesting, water supply networks, and water purification facilities, water tanks, water towers, water pipes including old aqueducts. Atmospheric water generators are in development. Drinking water is often collected at springs, extracted from artificial borings (wells) in the ground, or pumped from lakes and rivers. Building more wells in adequate places is thus a possible way to produce more water, assuming the aquifers can supply an adequate flow. Other water sources include rainwater collection. Water may require purification for human consumption. This may involve the removal of undissolved substances, dissolved substances and harmful microbes. Popular methods are filtering with sand which only removes undissolved material, while chlorination and boiling kill harmful microbes. Distillation does all three functions. More advanced techniques exist, such as reverse osmosis. Desalination of abundant seawater is a more expensive solution used in coastal arid climates. The distribution of drinking water is done through municipal water systems, tanker delivery or as bottled water. Governments in many countries have programs to distribute water to the needy at no charge. Reducing usage by using drinking (potable) water only for human consumption is another option.
Gavin Christopher Newsom (born October 10, 1967) is an American politician and businessman serving since 2019 as the 40th governor of California. A member of the Democratic Party, he served from 2011 to 2019 as the 49th lieutenant governor of California and from 2004 to 2011 as the 42nd mayor of San Francisco. Born and raised in San Francisco, Newsom graduated from Santa Clara University in 1989 with a Bachelor of Science in political science. Afterward, he founded the boutique winery PlumpJack Group in Oakville, California, with billionaire heir and family friend Gordon Getty as an investor. The company grew to manage 23 businesses, including wineries, restaurants, and hotels. Newsom began his political career in 1996, when San Francisco mayor Willie Brown appointed him to the city's Parking and Traffic Commission. Brown then appointed Newsom to fill a vacancy on the Board of Supervisors the next year and Newsom was first elected to the board in 1998. Newsom was elected mayor of San Francisco in 2003 and reelected in 2007. He was elected lieutenant governor of California in 2010 and reelected in 2014. As lieutenant governor, Newsom hosted The Gavin Newsom Show from 2012 to 2013 and in 2013 wrote the book Citizenville, which focuses on using digital tools for democratic change. Newsom was elected governor in 2018 and reelected in 2022. He faced criticism for his personal behavior and leadership style during the COVID-19 pandemic, which contributed to an unsuccessful recall effort in 2021.
Before 2018, only registered voters aged 21 and above could vote for the members of the House of Representatives and, in most of the states, for the state legislative chamber. Voting is not mandatory. In July 2019, a bill to lower the voting age to 18 years old was officially passed. Executive power is vested in the Cabinet, led by the Prime Minister. The prime minister must be a member of the House of Representatives, who in the opinion of His Majesty the King, commands the support of a majority of members. The Cabinet is chosen from members of both houses of Parliament. The Prime Minister is both the head of cabinet and the head of government. As a result of the 2018 general election, Malaysia was governed by the Pakatan Harapan (PH) political alliance, although Prime Minister Mahathir Mohamad resigned amid a political crisis in 2020. In March 2020, the Perikatan Nasional (PN) coalition formed under Prime Minister Muhyiddin Yassin, before Muhyiddin lost majority support and was replaced by deputy Prime Minister Ismail Sabri Yaakob, a veteran politician from the United Malays National Organisation (UMNO), in August 2021. As a result of the 2022 Malaysian general election, a hung parliament was elected. Anwar Ibrahim of the PH coalition was appointed as the new Prime Minister to lead the coalition government of PH, Barisan Nasional, Gabungan Parti Sarawak, Gabungan Rakyat Sabah and several other political parties and independents. Meanwhile, PN, the only political coalition not in the coalition government, became the Opposition.
Sources: en.wikipedia.org
The third government of Pedro Sánchez was formed on 21 November 2023, following the latter's election as prime minister of Spain by the Congress of Deputies on 16 November and his swearing-in on 17 November, as a result of the Spanish Socialist Workers' Party (PSOE) and Sumar being able to muster a majority of seats in the Parliament with external support from Republican Left of Catalonia (ERC), Together for Catalonia (Junts), EH Bildu, the Basque Nationalist Party (PNV), the Galician Nationalist Bloc (BNG) and Canarian Coalition (CCa) following the 2023 general election. It succeeded the second Sánchez government and has been the incumbent government of Spain since 21 November 2023, a total of 1,055 days, or 2 years, 10 months and 20 days. The cabinet comprises members of the PSOE (including its sister party, the Socialists' Party of Catalonia, PSC) and Sumar—with the involvement of Unite Movement (SMR), United Left (IU), the Communist Party of Spain (PCE), More Madrid (MM) and Catalonia in Common (Comuns)—as well as independents proposed by both parties.
ACC Synthase is 450-516 amino acid long sequence depending on the species of plant from which it is extracted. Though it is comparable in the species in which it is found, its COOH-terminal domain is more variable, leading to differences such as oligomerization. The COOH-terminal domain is responsible for oligomerization. In most ACC Synthase producing cells, ACC Synthase exists as a dimer. However, in some we find a monomer ("which is more active and efficient [than its dimer counterpart"). The structure of ACS has been largely determined via X-ray crystallography. Conservation of the residues in ACS's catalytic domain and sequence homology suggest that ACS catalyzes the synthesis of ACC in a similar fashion as other enzymes that require PLP as a cofactor. However, unlike many other PLP-dependent enzymes, Lys (278) is not the only residue that interacts with the substrate. The proximity of the electronegative oxygen from Tyr (152) to the C-γ-S bond suggests a crucial role in the formation of ACC. X-ray crystallography with aminoethoxyvinylglycine (AVG) a competitive inhibitor confirmed Tyrosine's role in the γ elimination. As of late 2007, 6 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1B8G, PDB: 1IAX, PDB: 1IAY, PDB: 1M4N, PDB: 1M7Y, and PDB: 1YNU.
Selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq) is a technique developed for the rapid identification of DNA binding specificities and affinities of full length monomeric and dimeric transcription factors in a fast and semi-high-throughput fashion. SMiLE-seq works by loading in vitro transcribed and translated “bait” transcription factors into a microfluidic device in combination with DNA molecules. Bound transcription factor-DNA complexes are then isolated from the device, which is followed by sequencing and then sequence data analysis to characterize binding motifs. Specialized software is used to determine the DNA binding properties of monomeric or dimeric transcription factors to help predict their in vivo DNA binding activity. SMiLE-seq combines three important functions differing from existing techniques: (1) The use of capillary pumps to optimize the loading of samples, (2) Trapping molecular interactions on the surface of the microfluidic device through immunocapture of target transcription factors, (3) Enabling the selection of DNA that is specifically bound to transcription factors from a pool of random DNA sequences.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.